Halozyme Therapeutics (HALO) Tops Q2 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Halozyme Therapeutics (HALO) Tops Q2 EPS by 6c

Halozyme Therapeutics (HALO) PT Raised to $21 at BMO Capital

August 8, 2018 6:59 AM EDT

BMO Capital raised its price target on Halozyme Therapeutics (NASDAQ: HALO) to $21.00 (from $19.00) while maintaining a Market Perform rating.

Analsyt Do Kim commented, "We raise our target to $21 from $19, as our probability of success for PEGPH20 in pancreatic cancer increases to 70% from 65%, following positive... More